🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

28 recruiting trials

for PsA (Psoriatic Arthritis)

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis NCT07443956NA4 sites📍 Birmingham📍 Coventry📍 Newcastle upon Tyne NHS Greater Glasgow and Clyde · Tests: Ixekizumab, Tirzepatide Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis NCT07298265n/a1 site📍 Toronto Charite University, Berlin, Germany A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting NCT07220824n/a21 sites📍 Bari📍 Brescia📍 Iesi Janssen Research & Development, LLC Oxidative Stress in Autoimmune Rheumatic Diseases NCT07536529n/a1 site📍 Larissa University of Thessaly Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058Phase 378 sites📍 Tucson📍 Fountain Valley📍 La Mesa Takeda · Tests: Zasocitinib A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) NCT06888193Phase 114 sites📍 Santa Monica📍 South Miami📍 Boston UCB Biopharma SRL · Tests: Bimekizumab Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis NCT05954364n/a1 site📍 Toronto Women's College Hospital Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620n/a1 site📍 Delafield Brain Inflammation Collaborative Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease NCT07280702Phase 41 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Deucravacitinib, Placebo Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy NCT06586281NA1 site📍 San Diego University of California, San Diego · Tests: Guselkumab APACHE Cohort (A Psoriatic Arthritis CoHort) NCT03768271n/a3 sites📍 Créteil📍 Montpellier📍 Paris Assistance Publique - Hôpitaux de Paris HIPPOCRATES Prospective Observational Study NCT05858528n/a1 site📍 Oxford University of Oxford · Tests: PEST screening questionnaire A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis NCT07315061Phase 21 site📍 Chengdu InventisBio Co., Ltd · Tests: D-2570, Placebo Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578Phase 12 sites📍 Charlestown📍 Birtinya Seismic Therapeutic AU Pty Ltd · Tests: S-4321 Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases NCT07087912Phase 42 sites📍 São Paulo📍 São Paulo University of Sao Paulo General Hospital · Tests: Dengue 1,2,3,4 (attenuated) vaccine Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients NCT05669833Phase 314 sites📍 Loxahatchee Groves📍 Plant City📍 Riverview University of Pennsylvania · Tests: Guselkumab, Golimumab A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) NCT07141004Phase 411 sites📍 Ahmedabad📍 Chandigarh📍 Chennai Johnson & Johnson Private Limited · Tests: Guselkumab Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor NCT07166315n/a1 site📍 Bath Adelphi Real World · Tests: observational study Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy NCT07150000n/a1 site📍 Bonn University of Bonn · Tests: Ex Vivo Assay Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis NCT06628206Phase 11 site📍 Amman LAPIX Therapeutics Inc. · Tests: LPX-TI641, Placebo Modifying PEST for Psoriatic Arthritis Screening NCT06382051NA30 sites📍 Calgary📍 Edmonton📍 Edmonton Novartis Pharmaceuticals · Tests: PEST Screening group AYLo - AutoimmunitY and Loss of y NCT06696027n/a1 site📍 Bonn University of Bonn · Tests: Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex… Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) NCT07611747Phase 417 sites📍 Alicante📍 Elche📍 Orihuela Instituto de Investigación Marqués de Valdecilla · Tests: Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis NCT06869551Phase 348 sites📍 Lancaster📍 Chicago📍 Indianapolis Bristol-Myers Squibb · Tests: Deucravacitinib, Placebo A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines NCT06671483Phase 3188 sites📍 Chandler📍 Phoenix📍 Phoenix Takeda · Tests: Zasocitinib, Active Comparator, Placebo Preventing Structural Damage in Early Psoriatic Arthritis NCT07486843Phase 41 site📍 Hong Kong Chinese University of Hong Kong · Tests: Amgevita 40Mg Solution for Injection, Methotrexate (Metoject® prefilled pen) Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial NCT07111494Phase 41 site📍 Milwaukee Medical College of Wisconsin · Tests: GLP-1 agonists, Nutrition Counseling REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases NCT07160231Phase 47 sites📍 Nijmegen📍 Maastricht📍 Tilburg Sint Maartenskliniek · Tests: JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy